The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has…
Browsing: HealthCare
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel therapeutics including…
Digital healthcare will play a major role in changing people’s lives and health as the development of internet-based medical care…
The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is…
Regent Pacific Group Limited (“Regent Pacific” or the “Company” and together with its subsidiaries, the “Group”; Hong Kong stock code:…
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development…
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics…
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”or the “Company”), a biopharmaceutical company focuses on the development of…
— Supplemental NDAs for Toripalimab filed — Expanding into infectious disease and collaborating with IMCAS and Lilly for COVID-19 neutralizing…
Profit Attributable to the Owners of the Company Increased by 153.3% Actively Develop New Products Reform and Replenish the Sales…
Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 “Sihuan Pharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) announced that…
Jacobson Pharma Corporation Limited (“Jacobson Pharma” or “the Group”; Stock Code: 2633.HK), a leading company engaged in the research, development,…
Maintained Steady Financial Performance under COVID-19 Pandemic Proceed with Hospital Group Business The board (the “Board”) of directors (the “Directors”)…
Novotech, the largest biotech specialist CRO in the Asia-Pacific region, was awarded the ‘2020 Frost & Sullivan Asia-Pacific CRO Company…
Revenue and Profit Attributable to Owners of the Company from Continuing Operations are RMB1,054.5 million and RMB170.5 million, respectively; Multiple…
Triple therapy specialist Professor Thomas Borody, famous for curing peptic ulcers using a triple antibiotic therapy saving millions of lives,…
免疫藥物公司AIM ImmunoTech(NYSE- American 交易代碼: AIM) 是一家致力於研究治療免疫疾病，病毒性疾病和多種類型癌症的療法的免疫藥物公司，今天提供了截至2020年6月30日的第二季度業務和臨床前/臨床更新。 2020年第二季度財務摘要： – 截至2020年6月30日，AIM的現金，現金等價物和有價證券為4030萬美元，而截至2019年12月31日為880萬美元。 – 截至2020年6月30日的第二季度的研發費用為146萬美元，而截至2019年6月30日的第二季度的研發費用為110萬美元。 – 截至2020年6月30日的第二季度的一般和行政支出為172萬美元，而截至2019年6月30日的第二季度的194萬美元。 公司的2020年6月30日完整財務業績包含在於2020年8月14日提交給美國證券交易委員會的10-Q表內，該表格可從www.sec.gov和公司網站上獲得。 “ AIM致力於滿足COVID-19和癌症等關鍵未滿足的醫療需求的極其重要且具有開創性的臨床前和臨床研究，這為我們在廣闊的潛在市場中提供了“多重目標”。根據這些多種表現，AIM支持這些試驗的策略是最大限度地增加直接授予臨床站點的第三方，非稀釋性資金，是我們在許多試驗中均已完成的。此外，截至2020年6月30日，我們的資產負債表上有超過4,000萬美元的現金，現金等價物和有價證券。因此，我們相信，我們非常有能力執行未來的戰略，反過來，我們預計將為股東帶來可觀的價值。” AIM首席執行官Thomas K. Equels說。 COVID-19常規更新：…
– Investigational first-in-class glucokinase activator, with a novel mode of action, focused on fixing the glucose sensor and restoring glucose…
MSD collaboration to investigate QBiotics’ lead molecule tigilanol tiglate in combination with KEYTRUDA(R) (pembrolizumab) Tigilanol tiglate is a novel, small…
Turnover (excl. the effect of “two-invoice system”) up 4.6% to RMB3,557.1 Million; Profit up 11.4% to RMB1,300.5 Million; Continuous Expansion…